SWOBY (Swedish Orphan Biovitrum AB) ROCE % : 10.59% (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Swedish Orphan Biovitrum AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Swedish Orphan Biovitrum AB's annualized ROCE % for the quarter that ended in Dec. 2024 was 10.59%.

Swedish Orphan Biovitrum AB ROCE % Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB ROCE % Chart

Swedish Orphan Biovitrum AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

12.76

9.17

9.08

8.82

9.25

Swedish Orphan Biovitrum AB Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															11.47	9.28	4.25	14.29	10.59

Swedish Orphan Biovitrum AB ROCE % Calculation

Swedish Orphan Biovitrum AB's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	512.062	/	( ( (7216.795 - 1861.547)	+	(6867.911 - 1147.019) )	/ 2 )
	=	512.062	/	( (5355.248	+	5720.892)	/ 2 )
	=	512.062	/	5538.07
	=	9.25 %

Swedish Orphan Biovitrum AB's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	604.824	/	( ( (7057.875 - 1358.979)	+	(6867.911 - 1147.019) )	/ 2 )
	=	604.824	/	( ( 5698.896	+	5720.892 )	/ 2 )
	=	604.824	/	5709.894
	=	10.59 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Swedish Orphan Biovitrum AB (OTCPK:SWOBY) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Swedish Orphan Biovitrum AB ROCE % Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Swedish Orphan Biovitrum AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (OTCPK:SWOBY) » Definitions » ROCE %

Traded in Other Exchanges

BIOVF:USA SOBI:Sweden SOBIs:UK 0MTD:UK B6E:Germany

Address

Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76

Website

https://www.sobi.com

Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).